{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:51:25Z","timestamp":1767135085418,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd007350","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2009,4,15]],"date-time":"2009-04-15T00:00:00Z","timestamp":1239753600000}}],"reference-count":41,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007350.pub2","type":"journal-article","created":{"date-parts":[[2009,4,15]],"date-time":"2009-04-15T15:23:00Z","timestamp":1239808980000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Thalidomide and thalidomide analogues for induction of remission in Crohn's disease"],"prefix":"10.1002","author":[{"given":"Ramesh","family":"Srinivasan","sequence":"first","affiliation":[{"name":"Booth Hall Children's Hospital; Charlestown Road Blackley Manchester UK M9 7AA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony K","family":"Akobeng","sequence":"additional","affiliation":[{"name":"Royal Manchester Children's Hospital; Oxford Road Manchester UK M13 9WL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,4,15]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD007350.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-2036.2007.03385.x","article-title":"A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease","volume":"26","author":"Mansfield","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1002\/14651858.CD007350.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1440-1746.2002.02564.x","article-title":"Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease","volume":"17","author":"Bariol","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"10.1002\/14651858.CD007350.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/gut.50.2.196","article-title":"Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease","volume":"50","author":"Bauditz","year":"2002","journal-title":"Gut"},{"issue":"6","key":"10.1002\/14651858.CD007350.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0016-5085(99)70276-3","article-title":"Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial","volume":"117","author":"Ehrenpreis","year":"1999","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD007350.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/00005176-200102000-00016","article-title":"Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: preliminary results","volume":"32","author":"Facchini","year":"2001","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"4","key":"10.1002\/14651858.CD007350.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1365-2036.2006.03211.x","article-title":"Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results","volume":"25","author":"Lazzerini","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1002\/14651858.CD007350.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1365-2036.2006.03239.x","article-title":"Thalidomide in luminal and fistulizing Crohn's disease resistant to standard therapies","volume":"25","author":"Plamondon","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1002\/14651858.CD007350.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1046\/j.1365-2036.2002.01273.x","article-title":"An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease","volume":"16","author":"Sabate","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1002\/14651858.CD007350.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0016-5085(99)70277-5","article-title":"An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease","volume":"117","author":"Vasiliauskas","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD007350.pub2-BIB0010|cit10","unstructured":"Ventura A Lazzerini M Thalidomide in pediatric inflammatory bowel diseases: Randomized controlled double-blind versus placebo multicentre study on the safety and effectiveness of thalidomide in the treatment of refractory Crohn's disease and ulcerative colitis ClinicalTrials.gov (NCT00720538) 2008"},{"issue":"4","key":"10.1002\/14651858.CD007350.pub2-BIB0011|cit11","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003574.pub2","article-title":"Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease","author":"Akobeng","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD007350.pub2-BIB0012|cit12","article-title":"Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease","author":"Behm","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD007350.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD007350.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1365-2036.2006.03156.x","article-title":"Review article: steroid resistance in inflammatory bowel disease - mechanisms and therapeutic strategies","volume":"25","author":"Creed","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1002\/14651858.CD007350.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1046\/j.1523-1747.2003.12565.x","article-title":"Thalidomide inhibits tumor necrosis factor-alpha production and antigen presentation by Langerhans cells","volume":"121","author":"Deng","year":"2003","journal-title":"J Invest Dermatol"},{"issue":"8","key":"10.1002\/14651858.CD007350.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.4049\/jimmunol.172.8.5103","article-title":"Thalidomide induces apoptosis in human monocytes by using a cytochrome c-dependent pathway","volume":"172","author":"Gockel","year":"2004","journal-title":"J Immunol"},{"issue":"929","key":"10.1002\/14651858.CD007350.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/pmj.79.929.127","article-title":"Thalidomide and its derivatives: emerging from the wilderness","volume":"79","author":"Gordon","year":"2003","journal-title":"Postgrad Med J"},{"issue":"9317","key":"10.1002\/14651858.CD007350.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT 1 randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD007350.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD007350.pub2-BIB0020|cit20","unstructured":"Higgins JPT Green S Assessment of study quality Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]; Section 6. In: The Cochrane Library, Issue 3 2005 Chichester, UK John Wiley & Sons, Ltd"},{"issue":"1","key":"10.1002\/14651858.CD007350.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"issue":"2","key":"10.1002\/14651858.CD007350.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00004836-200208000-00006","article-title":"Thalidomide as \"salvage\" therapy for patients with delayed hypersensitivity response to infliximab: a case series","volume":"35","author":"Kane","year":"2002","journal-title":"J Clin Gastroenterol"},{"issue":"9","key":"10.1002\/14651858.CD007350.pub2-BIB0023|cit23","first-page":"644","article-title":"Amelioration of experimental colitis by thalidomide","volume":"3","author":"Kenet","year":"2001","journal-title":"Isr Med Assoc J"},{"issue":"11","key":"10.1002\/14651858.CD007350.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.ejca.2006.04.004","article-title":"Thalidomide and lenalidomide in the treatment of multiple myeloma","volume":"42","author":"Kumar","year":"2006","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1002\/14651858.CD007350.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1053\/j.gastro.2006.02.014","article-title":"Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial","volume":"130","author":"Lemann","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD007350.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(61)90927-8","article-title":"Thalidomide and congenital abnormalities","volume":"2","author":"McBride","year":"1961","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/14651858.CD007350.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.4049\/jimmunol.159.10.5157","article-title":"Inhibition of IL-12 production by thalidomide","volume":"159","author":"Moller","year":"1997","journal-title":"J Immunol"},{"issue":"6","key":"10.1002\/14651858.CD007350.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1084\/jem.177.6.1675","article-title":"Thalidomide exerts its inhibitory action on tumour necrosis factor alpha by enhancing mRNA degradation","volume":"177","author":"Moreira","year":"1993","journal-title":"J Exp Med"},{"issue":"18","key":"10.1002\/14651858.CD007350.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1002\/14651858.CD007350.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","article-title":"Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease","volume":"117","author":"Rutgeerts","year":"1999","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD007350.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1084\/jem.173.3.699","article-title":"Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes","volume":"173","author":"Sampaio","year":"1991","journal-title":"J Exp Med"},{"issue":"3","key":"10.1002\/14651858.CD007350.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn's disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1002\/14651858.CD007350.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1002\/14651858.CD007350.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"issue":"6","key":"10.1002\/14651858.CD007350.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0016-5085(99)70299-4","article-title":"New life in a sleeper: thalidomide and Crohn's disease","volume":"117","author":"Sands","year":"1999","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1002\/14651858.CD007350.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn's disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1002\/14651858.CD007350.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1053\/j.gastro.2005.06.064","article-title":"A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease","volume":"129","author":"Schreiber","year":"2005","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD007350.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":"Maintenance therapy with certolizumab pegol for Crohn's disease","volume":"357","author":"Schreiber","year":"2007","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1002\/14651858.CD007350.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"issue":"9089","key":"10.1002\/14651858.CD007350.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/S0140-6736(05)64206-7","article-title":"Thalidomide in Crohn's disease","volume":"350","author":"Wettstein","year":"1997","journal-title":"Lancet"},{"issue":"11-12","key":"10.1002\/14651858.CD007350.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/j.1365-2036.2004.02285.x","article-title":"Intravenous CDP870, a PEGylated fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study","volume":"20","author":"Winter","year":"2004","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD007350.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T16:56:57Z","timestamp":1684947417000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD007350.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane IBD Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2009,4,15]]},"references-count":41,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007350.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,15]]}}}